Nuclein has filed a notice of an exempt offering of securities to raise $11,114,842.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Nuclein is raising up to $11,114,842.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Nuclein
Nuclein, LLC is an Austin, Texas-based company founded in 2017 with a vision to enable simple, affordable, rapid, and accurate testing for everyone. Its DASH Rapid PCR System runs the FDA-cleared and CLIA-waived DASH SARS-CoV-2 & Flu A/B Test and delivers lab-quality, point-of-care PCR results in 15 minutes. With a speed that is typically only available with antigen tests, the DASH Rapid PCR System was designed to offer low-cost, sensitive and specific results, with robust multiplexing across various sample types, and requires less than one minute of hands-on time. Nuclein has raised approximately $50 million to date, led by private equity firm Trinity Investors. In 2023, Nuclein merged with Minute Molecular Diagnostics, Inc., a Northwestern University spin-out that initially developed the DASH System.
To learn more, visit https://www.nuclein.com/
LinkedIn: https://www.linkedin.com/company/nucleindx/
Contact:
Alan Blake, Chief Executive Officer
https://www.linkedin.com/in/alanrblake/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
